163 related articles for article (PubMed ID: 38014249)
1. A Modified BPaL Regimen for Tuberculosis Treatment replaces Linezolid with Inhaled Spectinamides.
Ali MZ; Dutt TS; MacNeill A; Walz A; Pearce C; Lam H; Philp J; Patterson J; Henao-Tamayo M; Lee RE; Liu J; Robertson GT; Hickey AJ; Meibohm B; Gonzalez-Juarrero M
bioRxiv; 2024 Jun; ():. PubMed ID: 38014249
[TBL] [Abstract][Full Text] [Related]
2. The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis.
Hasan T; Medcalf E; Nyang'wa BT; Egizi E; Berry C; Dodd M; Foraida S; Gegia M; Li M; Mirzayev F; Morgan H; Motta I; Nguyen L; Schumacher S; Schlub T; Fox G
Clin Infect Dis; 2024 Mar; 78(3):730-741. PubMed ID: 37874021
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
Gomez GB; Siapka M; Conradie F; Ndjeka N; Garfin AMC; Lomtadze N; Avaliani Z; Kiria N; Malhotra S; Cook-Scalise S; Juneja S; Everitt D; Spigelman M; Vassall A
BMJ Open; 2021 Dec; 11(12):e051521. PubMed ID: 34862287
[TBL] [Abstract][Full Text] [Related]
4. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe.
Günther G; Guglielmetti L; Kherabi Y; Duarte R; Lange C;
Clin Microbiol Infect; 2024 Mar; ():. PubMed ID: 38490355
[TBL] [Abstract][Full Text] [Related]
5. Preserved Efficacy and Reduced Toxicity with Intermittent Linezolid Dosing in Combination with Bedaquiline and Pretomanid in a Murine Tuberculosis Model.
Bigelow KM; Tasneen R; Chang YS; Dooley KE; Nuermberger EL
Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32690647
[TBL] [Abstract][Full Text] [Related]
6. Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis.
Xu J; Li SY; Almeida DV; Tasneen R; Barnes-Boyle K; Converse PJ; Upton AM; Mdluli K; Fotouhi N; Nuermberger EL
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30833432
[TBL] [Abstract][Full Text] [Related]
7. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
[TBL] [Abstract][Full Text] [Related]
8. Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis.
Mulder C; Rupert S; Setiawan E; Mambetova E; Edo P; Sugiharto J; Useni S; Malhotra S; Cook-Scalise S; Pambudi I; Kadyrov A; Lawanson A; van den Hof S; Gebhard A; Juneja S; Sohn H
BMJ Glob Health; 2022 Jan; 7(1):. PubMed ID: 34992077
[TBL] [Abstract][Full Text] [Related]
9. Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid.
Howell P; Upton C; Mvuna N; Olugbosi M
BMJ Case Rep; 2021 Dec; 14(12):. PubMed ID: 34876446
[TBL] [Abstract][Full Text] [Related]
10. Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid.
Timm J; Bateson A; Solanki P; Paleckyte A; Witney AA; Rofael SAD; Fabiane S; Olugbosi M; McHugh TD; Sun E
PLOS Glob Public Health; 2023; 3(10):e0002283. PubMed ID: 37851685
[TBL] [Abstract][Full Text] [Related]
11. Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen.
Singh S; Gumbo T; Alffenaar JW; Boorgula GD; Shankar P; Thomas TA; Dheda K; Malinga L; Raj P; Aryal S; Srivastava S
Int J Antimicrob Agents; 2023 Dec; 62(6):106968. PubMed ID: 37726063
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Replacing Linezolid with OTB-658 in Anti-Tuberculosis Regimens in Murine Models.
Liu H; Zhu H; Fu L; Zhang W; Chen X; Wang B; Guo S; Ding Y; Wang N; Li D; Lu Y
Antimicrob Agents Chemother; 2023 Feb; 67(2):e0139922. PubMed ID: 36622240
[TBL] [Abstract][Full Text] [Related]
13. Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease.
Haley CA; Schechter MC; Ashkin D; Peloquin CA; Peter Cegielski J; Andrino BB; Burgos M; Caloia LA; Chen L; Colon-Semidey A; DeSilva MB; Dhanireddy S; Dorman SE; Dworkin FF; Hammond-Epstein H; Easton AV; Gaensbauer JT; Ghassemieh B; Gomez ME; Horne D; Jasuja S; Jones BA; Kaplan LJ; Khan AE; Kracen E; Labuda S; Landers KM; Lardizabal AA; Lasley MT; Letzer DM; Lopes VK; Lubelchek RJ; Patricia Macias C; Mihalyov A; Misch EA; Murray JA; Narita M; Nilsen DM; Ninneman MJ; Ogawa L; Oladele A; Overman M; Ray SM; Ritger KA; Rowlinson MC; Sabuwala N; Schiller TM; Schwartz LE; Spitters C; Thomson DB; Tresgallo RR; Valois P; Goswami ND;
Clin Infect Dis; 2023 Oct; 77(7):1053-1062. PubMed ID: 37249079
[TBL] [Abstract][Full Text] [Related]
14. Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts.
Oelofse S; Esmail A; Diacon AH; Conradie F; Olayanju O; Ngubane N; Howell P; Everitt D; Crook AM; Mendel CM; Wills GH; Olugbosi M; Del Parigi A; Sun E; Calatroni A; Spigelman M; Dheda K
Int J Tuberc Lung Dis; 2021 Jun; 25(6):453-460. PubMed ID: 34049607
[TBL] [Abstract][Full Text] [Related]
15. Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients.
van de Berg SEJ; Pelzer PT; van der Land AJ; Abdrakhmanova E; Ozi AM; Arias M; Cook-Scalise S; Dravniece G; Gebhard A; Juneja S; Handayani R; Kappel D; Kimerling M; Koppelaar I; Malhotra S; Myrzaliev B; Nsa B; Sugiharto J; Engel N; Mulder C; van den Hof S
BMC Public Health; 2021 Jul; 21(1):1404. PubMed ID: 34271884
[TBL] [Abstract][Full Text] [Related]
16. Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis.
Li S-Y; Tyagi S; Soni H; Betoudji F; Converse PJ; Mdluli K; Upton AM; Fotouhi N; Barros-Aguirre D; Ballell L; Jimenez-Navarro E; Nuermberger EL
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0156223. PubMed ID: 38376228
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Evaluation of Inhalational Spectinamide-1599 Therapy against Tuberculosis.
Gonzalez-Juarrero M; Lukka PB; Wagh S; Walz A; Arab J; Pearce C; Ali Z; Ryman JT; Parmar K; Temrikar Z; Munoz-Gutierrez J; Robertson GT; Liu J; Lenaerts AJ; Daley C; Lee RE; Braunstein M; Hickey AJ; Meibohm B
ACS Infect Dis; 2021 Oct; 7(10):2850-2863. PubMed ID: 34546724
[TBL] [Abstract][Full Text] [Related]
18. Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a short-course murine model of tuberculosis.
Lyons MA; Obregon-Henao A; Ramey ME; Bauman AA; Pauly S; Rossmassler K; Reid J; Karger B; Walter ND; Robertson GT
Antimicrob Agents Chemother; 2024 May; 68(5):e0101023. PubMed ID: 38501805
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Dynamic Efficacy Endpoints of the Nix-TB Trial.
Solans BP; Imperial MZ; Olugbosi M; Savic RM
Clin Infect Dis; 2023 Jun; 76(11):1903-1910. PubMed ID: 36804834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
